Insulet Corporation vs Hey Telo

About

Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics.